OncoCyte
SWOG to Use Oncocyte's DetermaIO Test in Cancer Biomarker Study
The DetermaIO test will be used to analyze triple negative breast cancer tissue as a secondary endpoint in the Phase III S1418 clinical trial.
Oncocyte Nets $3M VA Contract for DetermaRx Lung Cancer Prognostic Test
The test will be covered by the VA for five years to determine the risk of recurrence in early-stage lung cancer patients after surgery.
The company will compete against established comprehensive genomic sequencing assays, but hopes to provide better immunotherapy prediction.
Through its real-world evidence registry, the firm hopes to further validate its NSCLC recurrence risk test as a tool for guiding adjuvant treatment.
In Brief This Week: Oncocyte, Qiagen, Myriad Genetics, Iaso Biotherapeutics
News items for the week of May 31, 2021.
Mar 18, 2021
Feb 2, 2021
Oncocyte to Acquire Chronix Biomedical
Oct 21, 2020
Jan 10, 2020